Timothy P. Cripe
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
373
Citations
8,355
Est. group size
~13
Recurring co-author estimate
Active years
45
Publishing since 1982
Timothy P. Cripe's research focuses on developing and improving immune-based and virus-based therapies for pediatric and other solid tumors, including neuroblastoma, sarcomas, and gliomas. His work combines oncolytic viruses (viruses engineered to kill cancer cells), CAR-based cell therapies (immune cells engineered to target tumors), and drug combinations aimed at boosting anti-tumor immune responses, alongside related ethical and clinical-translation questions in gene and cell therapy.
Publication output was relatively steady through the late 2010s, dipped in 2021, then rose sharply from 2022 onward, with a notably large spike in 2023 and continued high output through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts
Molecular Therapy Oncology · 2026
- Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
Molecular Therapy Oncology · 2026
- Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors
Cancer Research Communications · 2026
- Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager
Molecular Therapy — Methods & Clinical Development · 2025
- Patient-centered long-term follow-up for gene therapies aligns with ethics and science
Molecular Therapy · 2025
- Development of a Pharmacokinetic (Pk) Mouse Serum Glp Elisa for An Anti-Cd19–Anti-Cd3 Diabody
SSRN Electronic Journal · 2025
- Combinatorial Immunotherapy of Mcam Targeting Chimeric Antigen Receptor Modified Expanded Natural Killer Cells and IL-15 Agonist Against Neuroblastoma
Transplantation and Cellular Therapy · 2025
- Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti-CD19–Anti-CD3 Diabody
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Clinical Trials or FDA-Approved Therapies? The Ethics of Sickle Cell Gene Therapy Access
The American Journal of Bioethics · 2025
- Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- 650 Enhanced cytotoxicity of anti-ROR1 CAR NK cells against glioblastoma via combined treatment with oncolytic virus and NKTR-255
Regular and Young Investigator Award Abstracts · 2025
- Proinflammatory Signaling in Ewing Sarcoma Tumor and Myeloid Cells Is Driven by Retroelement Activity and Counteracted by Reverse Transcriptase Inhibitors
SSRN Electronic Journal · 2025
- Cell-based potency assay for anti-CD3-anti-CD19 diabody
Journal of Immunological Methods · 2025
- Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma
Molecular Therapy Oncology · 2024
- Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
Molecular Therapy Oncology · 2024
- Cancer Research×14
- Molecular Therapy — Oncolytics×9
- Molecular Therapy Oncology×8
- Neuro-Oncology×7
- Regular and Young Investigator Award Abstracts×7
- Kevin A. Cassady
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jack Hedberg
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Nicholas Denton
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Roland W. Herzog
Biochemistry, Genetics and Molecular Biology · Indiana University
- Chelsea Bolyard
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile